Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients

This study has been terminated.
Information provided by:
ClinicalTrials.gov Identifier:
First received: November 6, 2007
Last updated: November 18, 2013
Last verified: November 2013
Evaluation of the effectiveness and the costs of a quantitative and qualitative nutritional supplementation in elderly patients

Condition Intervention Phase
Dietary Supplement: Renutryl 500
Dietary Supplement: Generique
Dietary Supplement: Generique + Renutryl 500
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients

Resource links provided by NLM:

Further study details as provided by Nestlé:

Primary Outcome Measures:
  • Nutritional Risk Index [ Time Frame: At J0, J21, J42 ]

Secondary Outcome Measures:
  • Measure of body mass index (BMI), Mini Nutritional Assessment, Fat mass,lean mass, serum albumin and transthyretin,Activities of Daily Living (ADL), ingesta and morbidity.
  • Tolerance [ Time Frame: Daily ]

Enrollment: 63
Study Start Date: October 2003
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: I
Active Comparator: II
oral nutrition
Dietary Supplement: Renutryl 500
Experimental: III
oral nutrition
Dietary Supplement: Generique
Experimental: IV
oral nutrition
Dietary Supplement: Generique + Renutryl 500


Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hospitalization into a geriatric care unit
  • age > 70 years
  • C reactive protein > 30 mg/l
  • 25 < albumin < 35 g/l
  • 130 < Na < 145 mmol/l
  • BMI < 22
  • weight loss > 10 % within the last 6 months
  • MNA < 23.5

Exclusion Criteria:

  • diabetes mellitus
  • severe digestive failure
  • enteral or parenteral nutrition
  • renal,cardiac or digestive failure
  • lactose intolerance
  • terminal phase severe pathology
  • MMS < 15
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560729

Hôpital Georges Clemenceau
Champcueil, France, 91750
Hopital Emile Roux
Limeil Brevannes, France, 94456
Hopital Charles RICHET
Villiers Le Bel, France, 95400
Sponsors and Collaborators
Study Director: Christian Aussel, PhD University PARIS V
  More Information

ClinicalTrials.gov Identifier: NCT00560729     History of Changes
Other Study ID Numbers: NCNF 0402 
Study First Received: November 6, 2007
Last Updated: November 18, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Nestlé:
elderly people

ClinicalTrials.gov processed this record on May 22, 2016